SUMMIT, N.J.--(BUSINESS WIRE)--May. 7, 2012--
Celgene Corporation (NASDAQ: CELG) today announced the appointment of
Thomas M. Moriarty as General Counsel and Corporate Secretary. In this
position, he will be responsible for global legal strategy at Celgene
and will serve on the company’s Management Committee.
Mr. Moriarty joins Celgene from Medco Health Solutions where he directed
all legal, regulatory, public policy and corporate governance functions
as General Counsel and Corporate Secretary since 2008. He also served as
President, Global Pharmaceutical Strategies, Senior Vice President,
Pharma Strategies & Solutions and Senior Vice President of Business
Development since joining Medco Health Solutions in June 2000.
Prior to joining Medco, Mr. Moriarty held a number of leadership
positions in the biopharmaceutical industry including Assistant General
Counsel – Pharma & North America for Merial Limited, a Merck & Co. and
Aventis Company, and previously as Senior Attorney for Merck & Co.
“Tom Moriarty brings a wealth of experience in global strategic and
legal healthcare management,” said Robert J. Hugin, Chairman and CEO of
Celgene Corporation. “His extensive legal background, as well as his
significant leadership experience will provide new insight and valuable
perspective on the increasingly complex global healthcare environment.”
Mr. Moriarty received his J.D. from the University of Virginia School of
Law and a bachelor’s degree in government and law from Lafayette College.
About Celgene
Celgene Corporation, headquartered in Summit, New Jersey, is an
integrated global biopharmaceutical company engaged primarily in the
discovery, development and commercialization of novel therapies for the
treatment of cancer and inflammatory diseases through gene and protein
regulation. For more information, please visit the company’s Web site at www.celgene.com.
Forward-Looking Statements
This press release contains forward-looking statements, which are
generally statements that are not historical facts. Forward-looking
statements can be identified by the words "expects," "anticipates,"
"believes," "intends," "estimates," "plans," "will," “outlook” and
similar expressions. Forward-looking statements are based on
management’s current plans, estimates, assumptions and projections, and
speak only as of the date they are made. We undertake no obligation to
update any forward-looking statement in light of new information or
future events, except as otherwise required by law. Forward-looking
statements involve inherent risks and uncertainties, most of which are
difficult to predict and are generally beyond our control. Actual
results or outcomes may differ materially from those implied by the
forward-looking statements as a result of the impact of a number of
factors, many of which are discussed in more detail in our Annual Report
on Form 10-K and our other reports filed with the Securities and
Exchange Commission.
Source: Celgene Corporation
For Celgene:
Investors:
908-673-9628
investors@celgene.com
or
Media:
908-673-2275
media@celgene.com
View printer-friendly version